Academic-Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigation (R01)
(Expiration date: May 8, 2013)
Houston Baker, Ph.D.
This announcement encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either animal or human in vivo imaging, image-guided and/or spectroscopic systems and methods designed to solve targeted cancer problems for cancer research, clinical trials, and/or clinical practice. The partners on each application will establish an inter-disciplinary, multi-institutional research team to work in a strategic alliance to implement a coherent strategy to develop and translate the proposed system or methods with potential for significant impact on preclinical, single, or multisite clinical studies. Partnerships must include at least one lead academic and one lead industrial organization large or small among their numbers. For either preclinical or clinical research, funding may be requested for limited additional copies of prototype systems and methods to optimize and validate them across different platforms and/or research sites. Each partnership is encouraged to plan to solve its choice of targeted cancer problem within the 5-year funding period. This announcement supports clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. It will not support commercial production.
Note that this revised announcement has provided:
- A revised definition of translational research consistent with the NCI Translational Research Working Group (TRWG) recommendations
- A definition of innovation within the context of the TRWG recommendation
- Examples of translational research for current commercial and next generation of imaging platforms
- Modified review criteria within the context of the TRWG recommendations.
The intent of this announcement is to encourage applications with a strong translational research focus. Note that investigators interested in the creation of research resources to assist in validation of imaging technologies are encouraged to explore collaboration with research networks (U01, U54) consistent with the announcement goals.
Paula M. Jacobs, Ph.D., is Associate Director, Cancer Imaging Program in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. She came to work at the NCI after 30 years in the pharmaceutical and medical device industries where she was a key developer of ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapeutics. More…